European Positive Opinions For Botox In Urinary Incontinence To Boost Allergan's Urology Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergen gains positive opinions in Europe for use of Botox in urinary incontinence associated with multiple sclerosis or spinal cord injury, paving the way for the company's further expansion into urology.
You may also be interested in...
Ipsen's New Chief Outlines Growth Plans In U.S., Emerging Markets
Tighter product focus and streamlined R&D will help double sales and triple profits by 2020, says CEO Marc de Garidel.
Botox For Migraine: How Will The Market Size Up?
The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.
Allergan Buys Global Rights To Serenity's Phase III Drug For Frequent Nighttime Urination
Allergan also will have right of first refusal for Ser-120 in pediatric bedwetting, though this use is in early stage development.